In patients with relapsed or refractory systemic lupus erythematosus, allogeneic CAR-NK cell therapy may offer a safe ...

A Phase II study was subsequently performed by the LBSL02/99 group, which enrolled 449 patients who met American College of Rheumatology (ACR) diagnostic criteria for SLE, had active SLE disease and ...

A Phase 2 study to evaluate the safety and efficacy of daxdilimab for treatment of active systemic lupus erythematosus (SLE) failed to meet its primary end point and did not obtain a significant ...

Cabaletta Bio is a biotech company with promising CARTA and CAART therapies for autoimmune diseases. Their main research project, CABA-201, targets patients suffering from SLE, opening up a huge ...

The following transcript is automatically generated and may contain typos or misspellings. Please listen to the episode for the most accurate language. Dr. Susan Manzi 0:00 Hello everyone. I'm Dr.

Within the 48-week treatment window, the Bruton’s tyrosine kinase (BTK) inhibitor triggered a 57.1% improvement in patients’ ...

Belimumab demonstrates notable efficacy for enhancing treatment outcomes among adults with active systemic lupus erythematosus when added to standard therapy. Belimumab demonstrates notable efficacy ...

In systemic lupus erythematosus, chronic spontaneous urticaria did not raise SLEDAI scores, but cylindruria, mucosal ulcers, ...

Thrombotic microangiopathy further decreases patient and renal survival in patients with SLE. Patients with systemic lupus erythematosus (SLE) with thrombotic microangiopathy (TMA) have lower ...

Objective To estimate the incidence of herpes zoster (HZ) and the incremental healthcare resource utilisation (HRU) and costs ...

Like in other chronic inflammatory disorders, achieving disease activity control in SLE requires the application of the treat-to-target strategy. This approach requires setting clear treatment targets ...